After spending more than a year reviewing the evidence relating to Lyme disease, a special independent Review Panel has unanimously agreed that no changes need to be made to IDSA’s 2006 Lyme disease guidelines. The panel determined that the guidelines were based on the best evidence available at the time and also supported by the evidence that has been published since. Released April 22, the Review Panel’s final report is available on IDSA’s website.
The special review was conducted following a voluntary agreement with Connecticut Attorney General Richard Blumenthal, who challenged the process used to develop IDSA’s 2006 Lyme disease guidelines on behalf of a group of patients and advocates and a small group of physicians who support a different treatment model. The Attorney General never questioned the scientific validity of IDSA’s guidelines but alleged conflicts of interest and a failure to consider divergent points of view. IDSA maintains that these assertions were unfounded. However, IDSA voluntarily agreed to a special, one-time review, confident that the guidelines and the process behind them would be validated.
< Previous Article | Next Article >